17 completed, 12 unknown, 6 not yet recruiting, 3 recruiting. 44 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 44 | Completed 17, Unknown 12, Not yet recruiting 6, Recruiting 3, Terminated 2, Withdrawn 2, Enrolling by invitation 1, Suspended 1 |
Follow Fluorouracil: new trials by email Literature Review of Fluorouracil trials Research Report on Fluorouracil
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer Zolbetuximab, Oxaliplatin, Folinic Acid - Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Phase 4 | Not yet recruiting | Astellas Pharma Global Development, Inc. | 50 | 2026-11-30 | 2026-09-21 |
| A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44) Pembrolizumab, Cisplatin, 5-Fluorouracil - Neoplasm Malignant, Gastric Neoplasms | Phase 4 | Not yet recruiting | Merck Sharp & Dohme LLC | 150 | 2026-11-06 | 2026-09-03 |
| Anti-EGFR Agents in Patients With Right-sided Advanced Colorectal Cancer With Wild-type RAS and AREG/EREG High Status Cetuximab (EGFR inhibitor), Bevacizumab, Irinotecan (CPT-11) - Colorectal Cancer | Phase 4 | Not yet recruiting | Gruppo Oncologico del Nord-Ovest | 280 | 2026-09-15 | 2026-07-24 |
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| A Prospective, Open-Label, Randomized Controlled Clinical Study Comparing Hepatic Arterial Infusion Chemotherapy (HAIC) With Capecitabine as Adjuvant Therapy After Radical Surgery for Malignant Biliary Tract Tumors Oxaliplatin + 5-Fluorouracil/Leucovorin, Capecitabine - Malignant Biliary Tract Tumors | Phase 4 | Recruiting | Zhai Wenlong | 90 | 2026-07-30 | 2026-09-11 |
| FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) - Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS) | Phase 4 | Not yet recruiting | Ye Xu | 42 | 2026-03-01 | 2026-03-03 |
| DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment Fluorouracil injection, Xeloda - Colorectal Neoplasms, Breast Neoplasms | Phase 4 | Recruiting | Rutgers, The State University of New Jersey | 100 | 2025-08-27 | 2025-11-13 |
| A Irinotecan Liposome Trial of in Advanced Neuroendocrine Carcinoma Irinotecan Hydrochloride Liposome Injection, 5-FU, LV - Neuroendocrine Carcinomas (NEC) | Phase 4 | Not yet recruiting | Beijing GoBroad Hospital | 45 | 2025-06-20 | 2025-06-11 |
| Combination Therapy of 5-Fluorouracil and CALcipotriol Versus 5-Fluorouracil in the Treatment of Actinic Keratosis 5FU-Calcipotriol, 5-FU 50 MG/ML Topical Cream - Actinic Keratoses | Phase 4 | Completed | Maastricht University Medical Center | 232 | 2024-09-04 | 2026-10-29 |
| Efficacy and Safety of Cryotherapy Versus 5-Fluorouracil in the Treatment of Actinic Keratosis Cryotherapy, 5Fluorouracil - Actinic Keratoses | Phase 4 | Enrolling by invitation | University of California, Davis | 73 | 2024-07-01 | 2026-07-06 |
| Microneedling vs. 5-Fluorouracil or Steroid Injections for Hypertrophic Scars and Keloids Microneedling with 5-Fluorouracil, Intralesional 5-fluorouracil, Intralesional Triamcinolone Acetonide - Keloid Scars, Hypertrophic Scar | Phase 4 | Completed | Alexandria University | 60 | 2023-01-12 | 2026-07-22 |
| Fractional CO2 Laser-assisted Cutaneous Delivery of Methotrexate Versus 5-fluorouracil in Stable Non-segmental Vitiligo Methotrexate, 5-fluorouracil, Fractional CO2 laser - Vitiligo | Phase 4 | Unknown | Assiut University | 50 | 2022-09-01 | 2022-05-09 |
| The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials Binimetinib, Encorafenib, Vemurafenib - Solid Tumors | Phase 4 | Recruiting | Pfizer | 210 | 2022-07-05 | 2026-10-19 |
| A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical Study Paprizumab combined with cisplatin and 5-FU - Temporal Bone Squamous Cell Carcinoma | Phase 4 | Unknown | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 30 | 2022-06-01 | 2022-07-06 |
| Frequency and Intensity of Local Reactions in Patients Treated With 4% 5-FU vs 4% 5-FU Associated With an Emollient Cream: a Randomised, Controlled Clinical Trial 5-fluorouracil 4% (Tolak), Dexeryl - Actinic Keratoses | Phase 4 | Completed | Pierre Fabre Medicament | 146 | 2021-02-16 | 2022-09-19 |
| Outpatient Performed Pterygium Surgery Study 5-Fluorouracil, Bevacizumab, Normal saline - Pterygium of Conjunctiva and Cornea | Phase 4 | Withdrawn | University of California, San Francisco | 2020-03-01 | 2021-08-12 | |
| Implementation of Pre-emptive Geno- and Phenotyping in 5-Fluorouracil- or Capecitabine-treated Patients 5-Fluorouracil - Colon Cancer, Stomach Tumor | Phase 4 | Unknown | Jessa Hospital | 250 | 2020-02-18 | 2020-02-13 |
| Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease Methyl Aminolevulinate (Mal) for Topical Administration, 16.8%, 1 Gram, 5Fluorouracil, Surgical excision - Bowen's Disease | Phase 4 | Completed | Maastricht University Medical Center | 250 | 2019-05-27 | 2025-05-06 |
| Strategies for Management of Recurrent Pterygium Bevacizumab, 5 fluorouracil - Recurrent Pterygium | Phase 4 | Unknown | University of Nottingham | 25 | 2017-01-01 | 2017-11-14 |
| Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC) Dose dense AC-P, Dose dense AC, FEC-D - Breast Cancer | Phase 4 | Terminated | Ottawa Hospital Research Institute | 2 | 2016-08-30 | 2025-12-04 |
Showing 20 of 44. Sign in to see all of them.
Colorectal Neoplasms (11) · Keratosis, Actinic (5) · Stomach Neoplasms (5) · Breast Neoplasms (3) · Head and Neck Neoplasms (3) · Neoplasms (3) · Colonic Neoplasms (2) · Esophageal Neoplasms (2) · Glaucoma (2) · Keloid (2) · Liver Neoplasms (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Adenocarcinoma Of Esophagus (1) · Anus Neoplasms (1)
Maastricht University Medical Center (3) · University of California, San Francisco (2) · Alexandria University (1) · Asan Medical Center (1) · Assistance Publique Hopitaux De Marseille (1) · Assiut University (1) · Astellas Pharma Global Development, Inc. (1) · Beijing GoBroad Hospital (1) · Cantonal Hospital of St. Gallen (1) · Centre Hospital Regional Universitaire de Limoges (1) · Centre Oscar Lambret (1) · China Meitan General Hospital (1) · Clinica Dermatologica Arbache ltda (1) · Gruppo Oncologico del Nord-Ovest (1) · Hoffmann-La Roche (1)
China (8) · United States (8) · France (6) · Netherlands (4) · Brazil (2) · Canada (2) · Germany (2) · Italy (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Austria (1) · Czechia (1)
An Lambaerts (1) · Chiara Cremolini, MD, PhD (1) · Daniel Catenacci (1) · Daniel Eisen, MD (1) · Gang Z Yu, Dr; PhD (1) · Gilles Freyer, MD (1) · Harminder Dua, Professor (1) · Howard S. Hochster, MD (1) · Hwei-Ming Wang, Chief (1) · John Hilton, Dr. (1)
PMID 16421419, PMID 19221274, PMID 26465781, PMID 27207349, PMID 27465252, PMID 27543222, PMID 28088997, PMID 28500658, PMID 28532759, PMID 28621489, PMID 28877312, PMID 29241779, PMID 29299592, PMID 30040817, PMID 30508548, PMID 30855743, PMID 30896781, PMID 31647464, PMID 31961446, PMID 32058557, PMID 32880186, PMID 33047438, PMID 33476658, PMID 33912999, PMID 35475852, PMID 37011024, PMID 40934140, PMID 41391634, PMID 42319271
2014 (2), 2023 (1), P30CA014599 (1)